Contract Research Development Manufacturing Organization

Cohance Lifesciences completed its USD 10 million investment in compulsorily convertible preferred stock of its US subsidiary NJ Bio Inc. NJ Bio is an ADC-focused CRDMO with USD 23.5-32.6 million annu